Immuneering Corporation (IMRX) Stock Score, Valuation & Financial Research

Immuneering Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for IMRX

Immuneering Corporation does not currently have a complete Wall Street Score. The stored market price is USD 4.10. These figures are a research snapshot, not a buy or sell recommendation.

What Immuneering Corporation does

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Immuneering Corporation is a clinical-stage oncology company that does not currently generate product revenue. Its business model relies on raising capital through equity offerings and other financing activities to fund the research and development of proprietary oncology product candidates, with the goal of eventually commercializing these therapies upon regulatory approval.

Products and services

  • The company is developing a pipeline of oncology product candidates, including atebimetinib, which is being studied in combination with mGnP for the treatment of pancreatic cancer.

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its drug substance and drug product for clinical trials. Source

Business strengths to evaluate

  • Proprietary platform and technologies Source

Business risks and research considerations

  • Limited operating history and no products approved for commercial sale Source
  • History of significant net losses and requirement for substantial additional capital Source
  • Unpredictable and lengthy regulatory approval processes Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

IMRX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 4.10
Market capitalization:
148.66M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -57.28M
Free cash flow:
USD -45.49M
Cash:
USD 41.32M
Total debt:
USD 3.63M
EPS:
USD -1.04

What stands out

  • Free cash flow is USD -45.49M, negative for the stored period.
  • The balance sheet shows USD 41.32M of cash versus USD 3.63M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 37.69M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for IMRX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can IMRX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is IMRX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for IMRX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of IMRX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research IMRX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.